Trial Profile
Effects of ARA 290 on neuropathic pain in patients with type 1 diabetes mellitus
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Cibinetide (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Type 1 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- 08 Aug 2016 According to an Araim Pharmaceuticals media release, this study is on schedule and results expected later in the year 2016.
- 05 Jan 2015 New trial record
- 15 Dec 2014 This proof-of-concept trial will be initiated in 2015, according to a North Shore-Long Island Jewish Health System media release.